Last reviewed · How we verify
Marihuana
Marihuana is a Small molecule drug developed by Mclean Hospital. It is currently in Phase 2 development.
Cannabis, also known as marijuana, is a non-chemically uniform psychoactive drug from the Cannabis plant, native to Central or South Asia. The main psychoactive component of cannabis is Tetrahydrocannabinol (THC), which has been used for centuries in various traditional medicines and for both recreational and entheogenic purposes.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Marihuana |
|---|---|
| Sponsor | Mclean Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder (NA)
- Perceptions of Proposed Warnings for Cannabis Edibles Packaging (NA)
- Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis (NA)
- Preventing Impaired Driving Among Adolescents (NA)
- Neuroimaging of Adolescent Cannabis Use Treatment (NA)
- Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
- Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marihuana CI brief — competitive landscape report
- Marihuana updates RSS · CI watch RSS
- Mclean Hospital portfolio CI
Frequently asked questions about Marihuana
What is Marihuana?
Who makes Marihuana?
What development phase is Marihuana in?
Related
- Manufacturer: Mclean Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing